What’s the current market cap for Celcuity stock?

Celcuity (CELC) has a market cap of $4.3bn as of June 17, 2026.

What is the P/E ratio for Celcuity stock?

The price to earnings (P/E) ratio for Celcuity (CELC) stock is 0 as of June 17, 2026.

Does Celcuity stock pay dividends?

No, Celcuity (CELC) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Celcuity dividend payment date?

Celcuity (CELC) stock does not pay dividends to its shareholders.

What is the beta indicator for Celcuity?

Celcuity (CELC) has a beta rating of 0.09. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Celcuity stock | $CELC Share Price

About Celcuity

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Ticker

$CELC

Sector

Health

Primary listing

NASDAQ

Employees

155

Headquarters

Minneapolis, United States

Website

www.celcuity.com

Celcuity Metrics

BasicAdvanced

$4.3bn

-

-$3.89

0.09

-

What the Analysts think about Celcuity

Analyst ratings (Buy, Hold, Sell) for Celcuity stock.

Bulls say / Bears say

Positive Phase 3 VIKTORIA-1 PIK3CA WT cohort results published in the Journal of Clinical Oncology demonstrated a median PFS of 16.6 months versus 1.9 months for fulvestrant alone (HR=0.14; p<0.0001), marking one of the most favorable hazard ratios reported in second-line HR+/HER2- advanced breast cancer (GlobeNewswire).

The FDA accepted Celcuity’s New Drug Application for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer and granted Priority Review with a PDUFA goal date of July 17, 2026, potentially paving the way for a commercial launch in Q3 2026 (GlobeNewswire).

Celcuity reported cash, cash equivalents, and short-term investments of $387.1 million as of March 31, 2026, providing runway into 2027 to support regulatory activities and initial commercial preparations (GlobeNewswire).

Celcuity's net loss grew to $52.8 million in Q1 2026 (versus $37.0 million in Q1 2025), and operating cash burn increased to $55.1 million, highlighting significant pre-commercialization spending that may necessitate further financing before profitability (GlobeNewswire).

Topline results for the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 trial are not yet disclosed and are expected in Q2 2026; a negative outcome could delay regulatory submissions and narrow the eligible patient pool (GlobeNewswire).

In the VIKTORIA-1 wild-type cohort, high rates of Grade 3+ adverse events—62.3% neutropenia, 19.2% stomatitis, and instances of rash and hyperglycemia—could pose tolerability challenges and impact market adoption (GlobeNewswire).

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

Celcuity Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Celcuity Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Celcuity News

AllArticlesVideos

What's Going On With Celcuity Stock On Tuesday?

Benzinga·2 weeks ago

Celcuity plunges after experimental breast cancer treatment data disappoints

Reuters·2 weeks ago

Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst

Benzinga·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Celcuity

Ticker

Employees

Celcuity Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Celcuity

Analyst Ratings

Bulls say / Bears say

Celcuity Financial Performance

Income Statement

Celcuity Earnings Performance

Earnings per share (EPS)

Celcuity News

What's Going On With Celcuity Stock On Tuesday?

Celcuity plunges after experimental breast cancer treatment data disappoints

Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst

Buy $CELC

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Celcuity/$CELC

About Celcuity

Ticker

Employees

Celcuity Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Celcuity

Analyst Ratings

Bulls say / Bears say

Celcuity Financial Performance

Income Statement

Celcuity Earnings Performance

Earnings per share (EPS)

Celcuity News

What's Going On With Celcuity Stock On Tuesday?

Celcuity plunges after experimental breast cancer treatment data disappoints

Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst

Buy $CELC

Upcoming events

No upcoming events

What’s the current market cap for Celcuity stock?

What is the P/E ratio for Celcuity stock?

Does Celcuity stock pay dividends?

When is the next Celcuity dividend payment date?

What is the beta indicator for Celcuity?

Bulls say / Bears say